Abstract: Derivative compounds of 11-nonyloxy-undec-8(Z)-eonic acid that mimic epoxide metabolites are provided. Also provided are compositions comprising a therapeutically effective amount of the derivative compounds. The present invention further provides methods for the use of such compositions for the treatment of renal or cardiovascular disease and/or related conditions.
Abstract: Disclosed is an absorbent for separation of carbon dioxide from mixed gases, comprising a mixture of i) a compound of the chemical formula 1 having one or more groups of three functional groups consisting of amino group attached to a tertiary carbon atom; carboxylate group; and hydroxyl group respectively, in a molecule, or a compound of the chemical formula 2 having one or more groups of two functional groups consisting of amino group attached to a quarternary carbon atom; and carboxylate group respectively in a molecule, and ii) an amine compound which promotes the reaction. The absorbent for separation of carbon dioxide of the present invention is advantageous economically, since its efficiency is excellent due to larger unit absorption amount of carbon dioxide, and the energy required for regeneration can be reduced due to the relatively wider difference of absorption amounts with temperature.
Type:
Application
Filed:
December 27, 2006
Publication date:
May 29, 2008
Inventors:
Jae Goo Shim, Jun Han Kim, Kyung Ryong Jang, Chung Kul Ryu, Hee Moon Eum, Hyun Soo Lim
Abstract: The present invention provides ester group-containing tertiary amine compounds of the formula (R1OCH2CH2)nN(CH2CH2CO2R2)3-n which, when used as additives in chemical amplification photolithography, can yield photoresists having a high resolution and an excellent focus margin. The present invention also provides a process comprising the step of subjecting a primary or secondary amine compound to Michael addition to an acrylic ester compound; a process comprising the steps of subjecting monoethanolamine or diethanolamine to Michael addition to an acrylic ester compound so as to form an ester group-containing amine compound and introducing a R1 group to the resultant ester group-containing amine compound; and a process comprising the step of effecting the ester exchange reaction of an ester group-containing tertiary amine with R2OH.
Type:
Grant
Filed:
June 12, 2006
Date of Patent:
May 27, 2008
Assignee:
Shin-Etsu Chemical Co., Ltd.
Inventors:
Takeru Watanabe, Koji Hasegawa, Takeshi Kinsho, Jun Hatakeyama
Abstract: This invention provides compounds having excellent antitumor activity, which are represented by the following formulae in which R1, R2, R3, m, n and R4 have the significations as given in the specification.
Abstract: One aspect of the invention relates to hexafluoroleucine and congeners thereof, and methods of making the compounds. Another aspect of the invention relates to the synthesis of protein cores comprising hexafluoroleucine and congeners thereof. Certain peptides comprising hexafluoroleucine and congeners thereof have been characterized using comparative biophysical studies. In general, the fluorinated peptides show higher thermal stability and enhanced resistance to chemical denaturation. Further, mixed hydrocarbon-fluorocarbon cores self-sort into homogeneous bundles, suggesting new avenues for the design and manipulation of protein-protein interfaces.
Abstract: Provided is a novel preparation method of (Z)-7-chloro-((S)-2,2-dimethylcyclopropanecarboxamido)-2-heptenoic acid represented by the following formula (1), a key intermediate of cilastatin used as a supplement to imipenem. The novel preparation method of the invention produces a pure (Z)-7-chloro-((S)-2,2-dimethylcyclopropanecarboxamido)-2-heptenoic acid, a key intermediate of cilastatin, by selective hydrolysis of E isomers.
Type:
Grant
Filed:
April 10, 2007
Date of Patent:
May 13, 2008
Assignee:
Wischem Co., Ltd.
Inventors:
Yang Rai Cho, Young Ji Shim, Eon Cheol Koo, Seon Yi Jeong, Byung Hwan Kim
Abstract: A developing solution containing at least one of compounds represented by the formulae <1>, <2> and <3> as defined herein, and having a pH of from 2 to 10; and a method for producing a lithographic printing plate, including imagewise exposing a lithographic printing plate precursor including an image recording layer and a support to cure the image recording layer in the exposed area, and developing the exposed lithographic printing plate precursor with an aqueous solution containing at least one of the compounds represented by the formulae <1>, <2> and <3> as defined herein and having a pH of 2 to 10 are provided.
Abstract: The invention provides the use of compounds of the formula (1) where R1, R2 are each independently C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, R3 is C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, —CHR5—COO? or —O?, R4 is M, hydrogen or an organic radical which optionally contains heteroatoms and has from 1 to 100 carbon atoms, B is an optionally substituted C1- to C30-alkylene group, D is an organic radical which optionally contains heteroatoms and has from 1 to 600 carbon atoms, X, Y are each independently O or NR6, R5, R6 are each independently hydrogen, C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, and M is a cation as gas hydrate inhibitors.
Abstract: This invention is directed to a process for making a salt of a carboxylic acid. The process comprises contacting a catalyst with an alkaline mixture comprising a primary alcohol. In one embodiment, for example, the catalyst comprises a metal support (preferably a metal sponge support) having a copper-containing active phase at the surface thereof. The support is resistant to deformation under the conditions of the dehydrogenation reaction. In another embodiment, the catalyst comprises a metal sponge having a copper-containing active phase at the surface thereof and a supporting structure containing at least 10% non-copper metal. This invention is also directed to copper-containing catalysts which may, for example, be used in the above process. This invention is further directed to processes for making such catalysts.
Type:
Grant
Filed:
April 11, 2001
Date of Patent:
February 12, 2008
Assignee:
Monsanto Technology LLC
Inventors:
David A. Morgenstern, Juan P. Arhancet, Howard C. Berk, William L. Moench, Jr., James C. Peterson
Abstract: The present invention is to provide a stabilized aqueous aminopolycarboxylate solution composition and a method of stabilizing the aminopolycarboxylate through preventing the same from caking. An aqueous aminopolycarboxylate solution composition containing an aminopolycarboxylate represented by the following general formula (1): in the formula, X may be the same or different and represents a hydrogen atom, an alkali metal atom, or an ammonium group, which has a D-form/L-form molar ratio of an aspartic acid skeleton of the aminopolycarboxylate of 1/0 to 0.7/0.3 or 0.3/0.7 to 0/1, has a solid concentration of 25 to 60 mass %, and has a pH value of not more than 11.
Abstract: The present invention provides a process for producing an optically active 2-allylcarboxylic acid derivative, which is useful as a pharmaceutical intermediate, from readily available and inexpensive starting materials by the process which can be practiced on a commercial scale in a simple and easy manner, and certain 2-allylcarboxamide derivatives, which are novel and important intermediates in that process. An N-allylcarboxamide derivative undergoes rearrangement reaction diastereoselectively in the presence of a base to give a 2-allylcarboxamide derivative, the resulting derivative is subjected to a carbamation reaction and solvolysis to give an optically active 2-allylcarboxylic acid ester, and then the ester obtained is stereoselectively hydrolyzed using an enzyme to produce 2-allylcarboxylic acid having a high optical purity. In addition, the present invention provides a 2-allylcarboxamide derivative compound which is a novel intermediate in the process of the present invention.
Type:
Grant
Filed:
April 16, 2004
Date of Patent:
October 16, 2007
Assignees:
Kaneka Corporation, Ono Pharmaceutical Co., Ltd.
Abstract: Presented are compounds represented by the following general formulas (I) and (II), for inhibiting cysteine protease legumain for modulating associated disease states in subjects
Abstract: Dipeptide derived inhibitors of the ?-secretase enzyme are provided which are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A? peptide in a mammal. The compounds of the invention provide useful methods of treatment by administration of these inhibitors to reduce A? peptide formation and in pharmaceutical compositions.
Type:
Grant
Filed:
March 8, 2005
Date of Patent:
October 2, 2007
Assignee:
Elan Pharmaceuticals, Inc.
Inventors:
Varghese John, Jay Tung, Roy Hom, Ashley Guinn, Lawrence Fang, Andrea Gailunas, Shumeye S. Mamo
Abstract: Disclosed herein are novel binaphthol derivatives and methods for the optical resolution of amino acids or amino alcohols and for the optical transformation of D, L-forms of amino acids using the same.
Type:
Grant
Filed:
January 30, 2006
Date of Patent:
September 11, 2007
Assignee:
Green of Life Co., Ltd.
Inventors:
Kwan Mook Kim, Won Woo Nam, Hyun Jung Park, Jik Chin
Abstract: Novel acetylamino benzoic acid compounds, methods of using and pharmaceutical compositions comprising an acetylamino benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.
Type:
Grant
Filed:
January 21, 2005
Date of Patent:
July 24, 2007
Assignees:
PTC Therapeutics, Inc., Amgen Inc.
Inventors:
Richard G. Wilde, Ellen M. Welch, James Jan Takasugi, Neil G. Almstead, Steven Marc Rubenstein, Holger Beckmann
Abstract: The instant invention describes a novel reaction that includes spontaneous racemization of an azalactone via enol tautomerization. This racemization results in improved yield and ee over other reactions previously described.
Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
Type:
Grant
Filed:
May 13, 2005
Date of Patent:
June 12, 2007
Assignees:
Elan Pharmaceuticals, Inc., Wyeth
Inventors:
Eugene D. Thorsett, Christopher M. Semko, Dimitrios Sarantakis, Michael A. Pleiss, Anthony Kreft, Andrei W. Konradi, Francine S. Grant, Darren B. Dressen, Susan Ashwell, Reinhardt B. Baudy, Louis J. Lombardo
Abstract: New salts of Meldonium, the method of their preparation, and pharmaceutical formulation on their basis have been described. The general formula of these salts is X?(CH3)3N+NHCH2CH2COOH where X? is an acid anion selected from the group of pharmaceutically acceptable acids. Practically non-hygroscopic and/or increased thermal stability and/or lasting action Meldonium hydrogen salts of fumaric acid, phosphoric acid, oxalic acid, maleic acid, and pamoic acid as well as Meldonium orotate and galactarate are especially suitable. Novel pharmaceutical formulations containing non-hygroscopic and/or increased thermal stability and/or and/or lasting action 3-(2,2,2-trimethylhydrazinium) propionate salts for oral parenteral, rectal, and transdermal introduction are concurrently described.
Abstract: The invention provides the use of compounds of the formula (1) where R1, R2 are each independently C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, R3 is C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, —CHR5—COO? or —O?, R4 is M, hydrogen or an organic radical which optionally contains heteroatoms and has from 1 to 100 carbon atoms, B is an optionally substituted C1- to C30-alkylene group, D is an organic radical which optionally contains heteroatoms and has from 1 to 600 carbon atoms, X, Y are each independently O or NR6, R5, R6 are each independently hydrogen, C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, and M is a cation as gas hydrate inhibitors.
Abstract: The present invention provides a novel crystal of alanine alkyl ester sulfonate having low hygroscopicity and low corrosiveness, which can be produced industrially economically. The present invention provides crystals of alanine alkyl ester sulfonates represented by formula (1): wherein R1 is a methyl group or an ethyl group, provided that when R1 is a methyl group, R2is an ethylphenyl group or a dimethylphenyl group; and when R1 is an ethyl group, R2 is a methyl group, a phenyl group, a chlorophenyl group, an ethylphenyl group, or a dimethylphenyl group.
Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.
Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
Type:
Grant
Filed:
October 7, 2002
Date of Patent:
January 23, 2007
Assignees:
Elan Pharmaceuticals, Inc., Wyeth
Inventors:
Michael S. Dappen, Darren B. Dressen, Francine S. Grant, Michael A. Pleiss, Cynthia Y. Robinson, Dimitrios Sarantakis, Eugene D. Thorsett
Abstract: This invention relates to a method of treating a disorder selected from OCD, agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, PTSD, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia by administering a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl; and R2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The invention also relates to a method of treating the above disorders by administering the compound (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid.
Type:
Grant
Filed:
December 12, 2003
Date of Patent:
January 16, 2007
Assignee:
Pfizer Inc.
Inventors:
David James Dooley, Charles Price Taylor, Jr., Andrew John Thorpe, David Juergen Wustrow
Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.
Abstract: Novel urea and urethane derivatives of general formula (I) in which R1, R2, R3, R5, R5?, X, Y, B, m, n and o are as defined in Patent Claim 1, and physiologically acceptable salts or solvates thereof are integrin inhibitors and can be employed for combating thromboses, cardiac infarction, coronary heart disease, arteriosclerosis, inflammation, tumors. Osteoporosis, infections and restenosis after angioplasty or in pathological processes maintained or propagated by antiogenesis.
Type:
Grant
Filed:
November 30, 2001
Date of Patent:
November 14, 2006
Assignee:
Merck Patent GmbH
Inventors:
Wolfgang Staehle, Alfred Jonczyk, Oliver Schadt, Simon Goodman
Abstract: One aspect of the invention relates to hexafluoroleucine and congeners thereof, and methods of making the compounds. Another aspect of the nvention relates to the synthesis of protein cores comprising hexafluoroleucine and congeners thereof. Certain peptides comprising hexafluorleucine and congeners thereof have been characterized using comparative biophysical studies. In general, the fluorinated peptides show higher thermal stability and enhanced resistance to chemical denaturation. Further, mixed hydrocarbonfluorocarbon cores self-sort into homogeneous bundles, suggesting new avenues for the design and manipulation of protein-protein interfaces.
Abstract: Compounds containing a specific saturated or unsaturated branched chain terminal group; a polar leading group; and a long-chain aliphatic, non-cyclic, saturated or unsaturated, substituted or unsubstituted, hydrocarbon group linking them; and having anti-cancer, immunosuppression alleviation, immune boosting and anti-inflammation activity.
Abstract: Compounds having the formula: are disclosed. M1 and M2 are the same or different and are transition metal atoms or ions; Z2 and Z3, independently, are the atoms necessary to complete a 3–12 membered heterocyclic ring; Z1 is an alkylene or arylene group; Q1 and Q2 are the same or different and are electron withdrawing groups; L1 and L3, taken together, represent —O—CR13—O—; L2 and L4, taken together, represent —O—CR14—O—; and R13 and R14 are the same or different and are selected from the group consisting of alkyl groups and aryl groups or R13 and R14 represent alkylene or arylene groups that are directly or indirectly bonded to one another. Methods for making such compounds are also disclosed, as are intermediates which can be used in their preparation. Also disclosed are methods for carrying out C—H insertion reactions using bis-transition metal catalysts, such as the above compounds. Procedures for preparing d-threo methylphenidate, tolterodine, CDP-840, nominfensine, and sertraline, are described.
Type:
Grant
Filed:
April 5, 2004
Date of Patent:
September 19, 2006
Assignee:
The Research Foundation of State University of New York
Abstract: Compounds containing a specific branched chain end terminal group, which is isopropyl, sec.-butyl, or tert.-butyl; a polar leading group; and long-chain aliphatic, non-cyclic, saturated or unsaturated, hydrocarbon group linking them; and having anti-cancer and immune boosting activity.
Abstract: Compounds of formula (I, II, or III), wherein X is OH; Y is OH, H, lower alkyl of one to six carbons or heteroatoms or F; Z and Z? are independently H, lower alkyl or Q3Si where Q is lower alkyl or aryl; n is 3–50; n? is 2–50; A and B are independently a) alkyl of one to ten carbons or heteroatoms, b) aryl of four to ten carbons or heteroatoms, c) cyclic of three to ten carbons or heteroatoms, or moieties of the formulas (d, e, or f); R1–R11 groups are each independently hydrogen, alkyl of one to ten carbons or heteroatoms, aryl of 4 to 14 carbons or heteroatoms, arylalkyl of five to twenty carbons or heteroatoms; unsubstituted carbonyl or substituted carbonyl. Heteroatoms are nitrogen, oxygen, silicon or sulfur. At least one of A or B, or both A and B are d), e), or f). The compounds of formula (I) inhibit protease enzymes and can be used as pharmaceuticals.
Type:
Grant
Filed:
March 29, 2005
Date of Patent:
August 8, 2006
Assignee:
Research Foundation of State University of New York
Inventors:
Scott McN. Sieburth, Alfred M. Mutahi, Chien-An Chen
Abstract: The present invention relates to a process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides of the formula I, in which the anions X are physiologically acceptable anions, and their analogs, which are effective inhibitors of the blood coagulation factor Xa and which can be used, for example, for preventing thromboses. The process according to the invention comprises the coupling of 2-[2-acetylamino-3-(4-amidinophenyl)propionylamino]-2-cyclohexylacetic acid, which is obtained from 2-[2-acetylamino-3-(4-cyanophenyl)acryloylamino]-2-cyclohexylacetic acid by asymmetric hydrogenation and conversion of the cyano group into the amidine, or a salt thereof, with a 3-(2-amino-2-carbamoylethyl)-1-methylpyridinium salt or a salt thereof. The invention furthermore provides starting materials and intermediates for this process, processes for their preparation and acetyl-(S)-4-amidiniophenylalanyl-(S)-cyclohexylglycyl-(S)-(1-methyl-3-pyridinio)alaninamide as ditosylate salt.
Type:
Grant
Filed:
June 17, 2004
Date of Patent:
August 1, 2006
Assignee:
Sanofi-Aventis Deutschland GmbH
Inventors:
Gerhard Breipohl, Wolfgang Holla, Heiner Jendralla, Gerhard Beck
Abstract: The present invention relates to a method for introducing an amino group into an organic acid or an organic ester by reacting an organic salt or an organic ester and ammonia under high-temperature and high-pressure water conditions, a method for synthesizing an amino acid or an amino ester by the above method, and a method for manufacturing an amino acid compound by synthesizing an amino acid or an amino ester by the above method and separating and refining it with an ion exchange resin.
Type:
Grant
Filed:
October 30, 2001
Date of Patent:
July 4, 2006
Assignee:
National Institute of Advanced Industrial Science and Technology
Abstract: This invention relates to certain ?-amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.
Type:
Grant
Filed:
March 27, 2003
Date of Patent:
June 20, 2006
Assignee:
Warner-Lambert Company
Inventors:
Nancy Sue Barta, Jacob Bradley Schwarz, Andrew John Thorpe, David Juergen Wustrow
Abstract: The present invention is directed to hydroxamate-containing inhibitors of cysteine and serine proteases. Methods for the use of the protease inhibitors are also described.
Type:
Grant
Filed:
November 20, 2003
Date of Patent:
June 13, 2006
Assignee:
Cephalon, Inc.
Inventors:
Kurt Allen Josef, John P. Mallamo, Ron Bihovsky
Abstract: One aspect of the present invention relates to a method for the kinetic resolution of racemic and diastereomeric mixtures of chiral compounds. The critical elements of the method are: a non-racemic chiral tertiary-amine-containing catalyst; a racemic or diastereomeric mixture of a chiral substrate, e.g., a cyclic carbonate or cyclic carbamate; and a nucleophile, e.g., an alcohol, amine or thiol. A preferred embodiment of the present invention relates to a method for achieving the kinetic resolution of racemic and diastereomeric mixtures of derivatives of ?- and ?-amino, hydroxy, and thio carboxylic acids. In certain embodiments, the methods of the present invention achieve dynamic kinetic resolution of a racemic or diastereomeric mixture of a substrate, i.e.
Abstract: The present invention provides a process for preparing 3-amino-2-hydroxypropionic acid derivatives (1) which does not use dangerous reagents, is economically advantageous, and is suitable for an industrial production, which process comprises: treating N-protected-3-amino-2-hydroxypropionic acid derivatives (2) having a steric configuration at 2-position carbon reverse to that of derivatives (1) with a leaving group-introducing agent to convert into N-protected-3-aminopropionic acid derivatives (3), then treating the derivatives with a basic substance to convert into substituted-3-amino-2-hydroxypropionic acid derivatives (4) having an inverted steric configuration at 2-position carbon, and then converting the derivatives into 3-amino-2-hydroxypropionic acid derivatives (1).
Type:
Grant
Filed:
June 26, 2001
Date of Patent:
June 6, 2006
Assignee:
Kaneka Corporation
Inventors:
Hiroshi Murao, Koki Yamashita, Toshihiro Takeda, Yasuyoshi Ueda
Abstract: A metal chelating composition having the formula: wherein Q is a carrier; S1 is a spacer; L is -A-T-CH(X)— or —C(?O)—; A is an ether, thioether, selenoether, or amide linkage; T is a bond or substituted or unsubstituted alkyl or alkenyl; X is —(CH2)kCH3, —(CH2)kCOOH, —(CH2)kSO3H, —(CH2)kPO3H2, —(CH2)kN(J)2, or —(CH2)kP(J)2, preferably —(CH2)kCOOH or —(CH2)kSO3H; k is an integer from 0 to 2; J is hydrocarbyl or substituted hydrocarbyl; Y is —COOH, —H, —SO3H, —PO3H2, —N(J)2, or —P(J)2, preferably, —COOH; Z is —COOH, —H, —SO3H, —PO3H2, —N(J)2, or —P(J)2, preferably, —COOH; and i is an integer from 0 to 4, preferably 1 or 2.
Type:
Grant
Filed:
September 22, 2003
Date of Patent:
April 25, 2006
Assignee:
Sigma-Aldrich Co.
Inventors:
William K. Kappel, Venkatappa Viswanatha, Handong Li, Richard J. Mehigh, John G. Dapron
Abstract: Compounds having the formula are useful for treating conditions which arise from or are exacerbated by angiogenesis. Also disclosed are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.
Type:
Grant
Filed:
August 6, 2003
Date of Patent:
April 18, 2006
Assignee:
Abbott Laboratories
Inventors:
Nwe Y. BaMaung, Richard A. Craig, Jack Henkin, Megumi Kawai, Xenia B. Searle, George S. Sheppard, Jieyi Wang
Abstract: The present invention relates to novel processes for the preparation of optically active 3-aminocarboxylic acids and their esters, in particular processes for the preparation of optically active compounds of the formula IA or IB as free bases or as acid addition salts thereof, in which the radicals are as defined in the description; in particular using the catalytic hydrogenation of olefinic precursors in the presence of platinum on alumina as a catalyst and the removal of chiral auxiliary groups from salt precursors; and novel process sections in the route for their synthesis, and processes for the preparation of biologically, in particular pharmacologically, active compounds, which comprise the novel processes.
Type:
Grant
Filed:
December 6, 2002
Date of Patent:
March 28, 2006
Assignee:
Ciba Specialty Chemicals Corporation
Inventors:
Kai-Uwe Schöning, Martin Studer, Hans Jürg Kirner, Stephan Burkhardt
Abstract: The present invention provides illudin analogs of the general formula (I): where R1 is (CH2)n—X—Y or H; n is 0 to 4; X is O or S or N or absent; and Y is an optionally substituted (C1-C8)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C4)alkyl or cyclo(C3-C6)alkyl optionally comprising one or more heteroatoms; a monosaccharide, an amino acid residue, or H when n is 2-4; R2 is absent; or R1 and R2 together comprise a 5-7 membered cyclic ring; R3 is (C1-C4)alkyl or H; R4 is H, SCH2CO2 (C1-C4)alkyl, O—(C5-C12)aryl or —S—(C5-C12)aryl; R5 is H, OH or absent; R6 is (C1-C4)alkyl or absent; R7 is OH or OSi((C1-C4)alkyl)3; or R6 and R7 together are ethylenedioxy; R8 is optionally substituted (C1-C4)alkyl; and the bonds represented by ----- are individually present or absent. The invention further provides dimers comprising analogs of formula (I).
Type:
Grant
Filed:
October 27, 2003
Date of Patent:
January 17, 2006
Assignee:
The Regents of the University of California
Abstract: Novel compounds of formula (I) are described wherein: R1=(CH2)mCH3 where m is 0 or an integer in the range from 1 to 16, or an alkenyl, alkynyl, alkoxy, alkylthio, or alkyl sulfinyl group having from 2 to 17 carbon atoms; R2=H, CH3 or CH2CH3; R3=H or CH3; R4H or CH3; R5=lower alkyl having from 1 to 5 carbon atoms; n is an integer in the range from 1 to 3, and X is carboxyl (COOH) or carbalkoxy (COOR5), cyano (C?N), phosphonic acid (PO3H2), phosphonate ester (PO3[R5]2) or 5-tetrazole, and pharmaceutically acceptable salts thereof. Preferably, the compounds are optically pure enantiomers of the R— or S—configuration in which R3=R4=R5=H, R2=CH3 and R1 is a saturated aliphatic chain of one to five carbon atoms.
Type:
Grant
Filed:
March 25, 1999
Date of Patent:
January 10, 2006
Assignee:
University of Saskatchewan Technologies Inc.
Inventors:
Lillian E. Dyck, Bruce A. Davis, Ya-Dong Liu, David A. Durden, Alan A. Boulton, Brenda Kennedy, Kevin Rogers, I. Alick Paterson
Abstract: Compounds of formula (I, II or III), wherein X is OH; Y is OH, H, lower alkyl of one to six carbons or heteroatoms or F; Z and Z? are independently H, lower alkyl or Q3Si where Q is lower alkyl or aryl; n is 3-50; n? is 2-50; A and B are independently a) alkyl of one to ten carbons or heteroatoms, b) aryl of four to seven carbons or heteroatoms, c) cyclic of three to ten carbons or heteroatoms, or moieties of the formulas (d, e, or f); R1-R11 groups are each independently hydrogen, alkyl of one to ten carbons or heteroatoms, aryl of 4 to 14 carbons or heteroatoms, arylalkyl of five to twenty carbons or heteroatoms; unsubstituted carbonyl or substituted carbonyl. Heteroatoms are nitrogen, oxygen, silicon or sulfur. At least one of A or B, or both A and B are d), e), or f). The compounds of formula (I) inhibit protease enzymes and can be used as pharmaceuticals.
Type:
Grant
Filed:
June 11, 2002
Date of Patent:
November 1, 2005
Assignee:
The Research Foundation of State University of New York
Inventors:
Scott McN. Sieburth, Alfred M. Mutahi, Chien-An Chen
Abstract: The invention relates to a process for preparing highly functionalized ?-butyrolactams and ?-amino acids by reductive amination of mucohalic acid or its derivatives, and discloses a process for preparing pregabalin, a GABA analog with desirable medicinal activity.
Type:
Grant
Filed:
April 23, 2003
Date of Patent:
August 2, 2005
Assignee:
Warner-Lambert Company
Inventors:
Peter G. Blazecka, James Guy Davidson, III, Ji Zhang
Abstract: The present invention relates to compounds of the general formula: NO2-A-B wherein A is a saturated or unsaturated hydrocarbon chain of 14-26 carbon atoms and B is (CH2)n(COOH)m in which n is an integer from 0 to 2 and m is an integer from 0 to 2; or of general formula (I), wherein A? is a saturated or unsaturated hydrocarbon chain of 9-26 carbon atoms, X is oxygen or is absent and B? is (CH2)j(COOH)k in which j is an integer from 1 to 3 and k is 0 or 1; and the derivatives thereof in which the hydrocarbon chain includes one or more than one substitution selected from the group consisting of hydroxy, hydroperoxy, epoxy and peroxy. These compounds have biological activity, e.g. as anti-infective or anti-inflammatory agents.
Type:
Grant
Filed:
March 18, 2002
Date of Patent:
August 2, 2005
Assignees:
Children, Youth and Women's Health Service Incorporated, Peptech Limited
Inventors:
Antonio Ferrante, Christopher J. Easton, Ling Xia
Abstract: A compound of formula: wherein X is a spacer comprising one or more amino acid residues and Y comprises an aromatic group and related compositions and methods of use.
Type:
Grant
Filed:
December 21, 2001
Date of Patent:
July 12, 2005
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: Peptido and peptidomimetic compounds of the formula: wherein the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and synthetic methods for preparing such compounds are also provided.
Type:
Grant
Filed:
January 5, 1999
Date of Patent:
June 14, 2005
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Peter Scott Dragovich, Stephen Evan Webber, Thomas Jay Prins, Ru Zhou, Joseph Timothy Marakovits, Theodore O. Johnson, Jr., Jayashree Girish Tikhe
Abstract: A process for producing an optically active 3-azide-carboxylic acid ester by reacting an optically active 3-hydroxycarboxylic acid ester and a thionyl halide in the presence of a basic substance in an organic solvent to produce an optically active 3-halogenocarboxylic acid ester which is then reacted with an azide salt represented by the formula: MN3 (wherein M is an alkaline metal) in water or a mixture of water and a water soluble organic solvent.
Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
Type:
Grant
Filed:
November 15, 2001
Date of Patent:
May 31, 2005
Inventors:
Eugene D. Thorsett, Christopher M. Semko, Dimitrios Sarantakis, Michael A. Pleiss, Anthony Kreft, Andrei W. Konradi, Francine S. Grant, Darren B. Dressen, Susan Ashwell, Reinhardt Bernhard Baudy, Louis John Lombardo
Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.